Efficacy of levetiracetam in premature infants: our experience and review of the literature
Journal of Maternal-Fetal and Neonatal Medicine, cilt.32, sa.24, ss.4093-4096, 2019 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 32 Sayı: 24
- Basım Tarihi: 2019
- Doi Numarası: 10.1080/14767058.2018.1481946
- Dergi Adı: Journal of Maternal-Fetal and Neonatal Medicine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.4093-4096
- Anahtar Kelimeler: Levetiracetam, neonatal intensive care, premature
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: To evaluate levetiracetam (LEV) efficacy in preterm infants admitted in NICU. Study design: Clinical characteristics of 26 preterm infants treated with LEV were evaluated retrospectively. The results were compared with those of 44 preterm infants from the literature who were given LEV. Result: The mean gestational week of the infants receiving LEV was found as 26.7 ± 3.3 weeks, mean birth weight as 938 ± 561 g and mean dose of LEV as 17 ± 9.23 mg/kg. Overall seizure control rate with LEV was found as 65%, while seizure control was achieved by 11.5% when it was used as the first drug, 35% as the second drug and 15.3% as the third drug. The incidence of sepsis and intraventricular hemorrhage in seizure etiology was 73% in infants who received LEV. There was no side effect observed during LEV treatment. Conclusions: Seizure control was better achieved with LEV given as the 2nd antiepileptic in premature infants. Further studies with randomization of LEV and other antiepileptics in seizure control are needed.